Clinical study on the efficacy of short-term migraine preventive medications for vestibular migraine

Abstract

Between June 2022 and February 2023, in our clinic, 1,222 patients sought medical attention for dizziness. Among them, 205 patients screened positive for migraine, accounting for 16.8% of all dizziness cases. Of these migraine cases, 60 were confirmed as vestibular migraine (VM), representing 4.9% of all dizziness cases. A prospective study was conducted on 28 confirmed VM cases, tracking their progress for 4 weeks. The study aimed to assess the effectiveness of Migsis^® monotherapy. The headache evaluation relied on the frequency of analgesic use before and after treatment initiation. The study revealed a 28.6% improvement rate in headaches. However, the effect was considered insufficient, highlighting the need for combination therapy and long-term treatment. Dizziness was assessed using the Dizziness Handicap Inventory (DHI) score, measuring the impact on daily life. DHI scores averaged 44.2 ± 23.2 points at the initial visit and 25.1 ± 23.4 points at week 4, showing a significant improvement (p=0. 001). Based on Jacobson et al.’s report, a 46. 4% significant improvement was observed. Therefore, comprehensive and long-term treatment is necessary for VM, as monotherapy with migraine preventive drugs alone is inadequate. Vestibular rehabilitation has shown promise for VM, suggesting its inclusion as a future treatment option.